Advanced search
Publication Cover
Scandinavian Journal of Urology Volume 56, 2022 - Issue 3
Journal homepage
53
Views
0
CrossRef citations to date
0
Altmetric
Articles

Interpretation of composite endpoints in urology: an analysis of citation quality

Frederik M. JacobsenDepartment of Urology, Copenhagen University Hospital – Herlev and Gentofte Hospital, Copenhagen, DenmarkCorrespondence[email protected]
,
Klara Kvorning TernovDepartment of Urology, Copenhagen University Hospital – Herlev and Gentofte Hospital, Copenhagen, Denmark
,
Alexander B. NolsøeDepartment of Urology, Copenhagen University Hospital – Herlev and Gentofte Hospital, Copenhagen, Denmark
,
Peter Busch ØstergrenDepartment of Urology, Copenhagen University Hospital – Herlev and Gentofte Hospital, Copenhagen, Denmark
,
Mikkel FodeDepartment of Urology, Copenhagen University Hospital – Herlev and Gentofte Hospital, Copenhagen, Denmark
,
Jens SønksenDepartment of Urology, Copenhagen University Hospital – Herlev and Gentofte Hospital, Copenhagen, Denmark
&
Christian Fuglesang S. JensenDepartment of Urology, Copenhagen University Hospital – Herlev and Gentofte Hospital, Copenhagen, Denmark
 show all
Pages 206-212 | Received 06 Dec 2021, Accepted 23 Mar 2022, Published online: 11 Apr 2022

References

  • Palileo-Villanueva LM, Dans AL. Composite endpoints. J. Clin. Epidemiol. 2020;128:P157–P158.
  • Mccoy CE. Understanding the use of composite endpoints in clinical trials. West. J. Emerg. Med. 2018;19(4):631–634.
  • Cannon CP. Clinical perspectives on the use of composite endpoints. Control Clin. Trials. 1997;18(6):517–529.
  • Ferreira-González I, Permanyer-Miralda G, Busse JW, et al. Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns. J. Clin. Epidemiol. 2007;60(7):651–657.
  • Chi GYH. Some issues with composite endpoints in clinical trials. Fundam. Clin. Pharmacol. 2005;19:609–619.
  • Lavallée LT, Dahm P, Breau RH. Evidence-based urology in practice: composite endpoints. BJU Int. 2010;106(5):610–612.
  • Bowater RJ, Lilford RJ. Clinical effectiveness in cardiovascular trials in relation to the importance to the patient of the end-points measured. J. Eval. Clin. Pract. 2011;17:547–553.
  • Mottet N, Bastian P, Bellmunt J, et al. EAU-EANM-ESTRO-ESUR-SIOG: guidelines on prostate cancer. Eur. Assoc. Urol. 2020;79:1–182.
  • Witjes JA, Bruins M, Cathomas R, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer 2020. European Association of Urology Guidelines. 2020 Ed. 2020. Available from: http://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/. LK – Muscle-invasive and Metastatic Bladder Cancer Uroweb%7C. http://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/%7C. FG – 0.
  • Ljungberg B, Albiges L, Bensalah K, et al. EAU guidelines. Edn. presented at the EAU annual congress Amsterdam 2020. Eur. Urol. 2020;67:913–924.
  • Gravas S, Cornu J, Gacci M, et al. EAU guidelines on non-neurogenic male LUTS incl. BPO. Eur. Urol. 2020;67(6):1099–1109.
  • Türk C, Petřík A, Sarica K, et al. EAU guidelines on interventional treatment for urolithiasis. Eur. Urol. 2016;69(3):475–482.
  • EAU: EAU guidelines on sexual and reproductive health. Eur. Assoc. Urol. 2020;79:232.
  • Babjuk M, Oosterlinck W, Sylvester R, et al. Guidelines on bladder cancer (TaT1 and CIS). Eur. Urol. 2012;31:1–36.
  • Smith MR, Saad F, Coleman R, et al. Denosumab and bone metastasis-free survival in men with castration-resistant prostate cancer: results of a global phase 3, randomised, placebo-controlled trial. Lancet. 2013;379:39–46.
  • Parekh DJ, Reis IM, Castle EP, et al. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet. 2018;391:2525–2536.
  • Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–1482.
  • McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. 2019;349(25):2387–2398.
  • Pace KT, Ghiculete D, Harju M, et al. Shock wave lithotripsy at 60 or 120 shocks per minute: a randomized, double-blind trial. J. Urol. 2005; 174:595–599.
  • Sønksen J, Barber NJ, Speakman MJ, et al. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. Eur. Urol. 2015; 68:643–652.
  • Madan RA, Gulley JL. Prostate cancer: intermediate efficacy end points to assess modern therapies. Nat Rev Urol. 2013;10(12):686–687.
  • Lee GT, Kang DI, Ha YS, et al. Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction. Br. J. Cancer. 2014;110(6):1634–1644.
  • Bauchner H, Golub RM, Fontanarosa PB. Reporting and interpretation of randomized clinical trials. J. Am. Med. Assoc. 2019;322:732–735.
  • Ferreira-González I, Busse JW, Heels-Ansdell D, et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. Br. Med. J. 2007;334:786–788.
  • Freemantle N, Calvert M, Wood J, et al. Composite outcomes in randomized trials: greater precision but with greater uncertainty? J. Am. Med. Assoc. 2003;289:2554–2559.
  • Cordoba G, Schwartz L, Woloshin S, et al. Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. BMJ. 2010;341:381.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.